Institutional members access full text with Ovid®

Representativeness of Participants in the Cancer Care Outcomes Research and Surveillance Consortium Relative to the Surveillance, Epidemiology, and End Results Program

Catalano, Paul J. ScD*,†; Ayanian, John Z. MD, MPP‡,§; Weeks, Jane C. MD, MSc; Kahn, Katherine L. MD¶,♯; Landrum, Mary Beth PhD; Zaslavsky, Alan M. PhD; Lee, Jeannette PhD**; Pendergast, Jane PhD††; Harrington, David P. PhD*,†

doi: 10.1097/MLR.0b013e318222a711
Online Article: Applied Methods

Background: The research goals of the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium are to determine how characteristics and beliefs of patients, providers, and health care organizations influence the treatments and outcomes of individuals with newly diagnosed lung and colorectal cancers. As CanCORS results will inform national policy, it is important to know how they generalize to the United States population with these cancers.

Research Design: This study assessed the representativeness of the CanCORS cohort of 10,547 patients with lung cancer (LC) or colorectal cancer (CRC) enrolled between 2003 and 2005. We compared characteristics (sex, race, age, and disease stage) with the Surveillance, Epidemiology, and End Results (SEER) population of 234,464 patients with new onset of these cancers during the CanCORS recruitment period.

Results: The CanCORS sample is well matched to the SEER Program for both cancers. In CanCORS, 41% LC/47% CRC were female versus 47% LC/49% CRC in SEER. African American, Hispanic, and Asian cases differed by no more than 5 percentage points between CanCORS and SEER. The SEER population is slightly older, with the percentage of patients older than 75 years 33.1% LC/37.3% CRC in SEER versus 26.9% LC/29.4% in CanCORS, and also has a slightly higher proportion of early stage patients. We also found that the CanCORS cohort was representative within specific SEER regions that map closely to CanCORS sites.

Conclusions: This study demonstrates that the CanCORS Consortium was successful in enrolling a demographically representative sample within the CanCORS regions.

*Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute

Department of Biostatistics

Department of Health Care Policy and Brigham, Harvard School of Public Health

§Division of General Medicine, Women's Hospital

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

RAND Corporation, Santa Monica

Division of General Internal Medicine and Health Services Research at the David Geffen School of Medicine at UCLA, Los Angeles, CA

**Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR

††Department of Biostatistics, University of Iowa College of Public Health, Iowa City, IA

The Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium was supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center at the Dana-Farber Cancer Institute (U01 CA093344) and the Primary Data Collection and Research Centers at the Harvard Medical School and Northern California Cancer Center (U01 CA093324); Dana-Farber Cancer Institute and Cancer Research Network (U01 CA093332); RAND and University of California, Los Angeles (U01 CA093348); University of Alabama at Birmingham (U01 CA093329); University of Iowa (U01 CA093339); University of North Carolina (U01 CA093326); and by a Department of Veteran's Affairs grant to the Durham VA Medical Center (U01 CDA093344 (MOU) and HARQ 03-438MO-03).

The authors declare no conflict of interest.

Reprints: Paul J. Catalano, ScD, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215-5450. e-mail: pcata@jimmy.harvard.edu.

© 2013 Lippincott Williams & Wilkins, Inc.